5-(ethylsulfonyl)-2-(naphthalene-2-yl)benzo(d)oxazole,
SMT C1100,
SMTC1100,
5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo(d)oxazole,
5-ethylsulfonyl-NBO,
Ezutromid,
945531-77-1,
SMT c1100,
BMN-195,
BMN 195,
UNII-645R07LF0D,
SMTC-1100,
VOX-C1100,
645R07LF0D,
5-(Ethylsulfonyl)-2-(naphthalen-2-yl)benzo(d)oxazole,
5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole,
5-Ethylsulfonyl-2-naphthalen-2-yl-1,3-benzoxazole,
Ezutromid [INN],
SMT-C1100,
SCHEMBL732212,
Benzoxazole, 5-(ethylsulfonyl)-2-(2-naphthalenyl)-,
BMN195,
SMTC1100,
CHEMBL1773683,
SMTC 1100,
DTXSID30241525,
BCP18328,
EX-A2333,
ZINC71297091,
BMN-195; SMT C1100,
AKOS030527030,
CS-5710,
DB12888,
SB19603,
HY-17614,
5-(Ethylsulfonyl)-2-(naphthalen-2-yl)benzo[D] oxazole,
D0Y7YD,
VOXC-1100,
Utrophin modulators (Duchenne muscular dystrophy),
Utrophin modulators (Duchennemuscular dystrophy), VASTox,
Utropine inducer (Duchenne muscular dystrophy), Summit/BioMarin,
Utrophin modulators (Duchenne muscular dystrophy), Summit/BioMarin,
Utorphin upregulators (Duchenne muscular dystrophy), VASTox/University of Oxford,